We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Speaker: Prof. Stephan Urban, German Center for Infection Research (DZIF) - Heidelberg Partner Site, Heidelberg, Germany
Professor Stephan Urban is head of the Translational Virology unit at the Department of Infectious Diseases, Molecular Virology at Heidelberg University Hospital. Between 2008 and 2012 he was Project coordinator of the BMBF-network “Innovative Therapies” and is now coordinating the Hepatitis D project within the German Center for Infection Research (DZIF) TTU Hepatitis.
Background: Hepatitis B (HBV) and Hepatitis D Virus (HDV) infection requires the interaction of the shared envelope proteins with the hepatocyte specific receptor sodium taurocholate cotransporting polypeptide (NTCP). This species-specific interaction is mediated by an evolutionary adaptation of an essential sequence (the receptor binding domain (RBD)) within the myristoylated preS1-domain of the HBV large surface protein (L-protein) to NTCP. Following the concept that chemically synthesized lipopeptides representing this RBD are potent inhibitors of hepadnaviral infection, both the identity of the long-sought HBV receptor was uncovered and the first approved entry inhibitor for HBV/HDV infection (bulevirtide/Hepcludex) was developed
Host: Dr. Tomàs Pumarola, Head of Microbiology Department. Vall d’Hebron University Hospital (Barcelona) - Dr. María Francesca Cortese, Main researcher Microbiology -Vall Hebron Institut de Recerca (VHIR)
Online attendance: https://gencat.zoom.us/j/85247866153
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.